DIAGNOS Announces Closing of a Private Placement
September 16 2019 - 04:00PM
DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX
Venture: ADK) (OTCQB: DGNOF), a leader in early detection of
critical health issues through the use of Artificial Intelligence
(AI), announces the closing of a private placement (“Private
placement”) of 2,750,000 units (each a “Unit”) issued at $0.20 per
Unit, for gross proceeds of $550,000, which represents $50,000 more
than what was previously announced on September 13, 2019. Each Unit
consists of;
- one common share (“Share”), and
- one stock warrant (“Warrant”) entitling the holder to purchase
one Share per Warrant at a price of $0.25 per Share, for a period
of 18 months ending March 16, 2021.
The proceeds will mainly be used to fund sales
and marketing as well as administrative expenses.
Shares issued as part of the Private placement
as well as the underlying Shares to be issued upon exercise of the
Warrants are subject to a statutory four-month hold period ending
January 16, 2020.
The Private placement remains subject to the
final acceptance by the TSX Venture Exchange and to the execution
of formal documentation.
All monies quoted in this press release shall be
stated and paid in lawful money of Canada.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time and has been cleared for
commercialization by several regulatory authorities such as Health
Canada, the U.S. Food and Drug Administration and the European
Union.
Additional information is available at
www.diagnos.com and www.sedar.com. For further information,
please contact:
Mr. André Larente, President |
DIAGNOS Inc. |
Tel: 450-678-8882 ext. 224 |
alarente@diagnos.ca |
This news release contains forward-looking information. There
can be no assurance that forward-looking information will prove to
be accurate, as actual results and future events could differ
materially from those anticipated in these statements. DIAGNOS
disclaims any intention or obligation to publically update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise. The forward-looking
information contained in this news release is expressly qualified
by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2023 to Mar 2024